This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

OncoMed Pharmaceuticals Presents Data From Demcizumab Phase 1b Clinical Study In Pancreatic Cancer At The 2014 Gastrointestinal Cancers Symposium

SAN FRANCISCO, Jan. 17, 2014 (GLOBE NEWSWIRE) -- OncoMed Pharmaceuticals, Inc. (Nasdaq:OMED), a clinical-stage company developing novel therapeutics that target cancer stem cells (CSCs), or tumor-initiating cells, presented data today from its ongoing Phase 1b clinical trial of demcizumab (OMP-21M18; anti-DLL4) in first-line Stage IV pancreatic cancer patients at the 2014 Gastrointestinal Cancers Symposium being held in San Francisco, California. These are the first reported data from the Phase 1b study of demcizumab with gemcitabine to include the addition of Abaxane ® (nab-paclitaxel). Demcizumab is part of OncoMed's collaboration with Celgene Corporation.

Dr. Antonio Cubillo of START-Madrid, the presenting author for the poster presentation commented, "Advanced pancreatic cancer is a challenging malignancy with poor survival outcomes for many patients and new drugs that can further improve outcomes are needed. The early data for the combination of demcizumab with Abraxane and gemcitabine are potentially encouraging both from a safety and clinical activity perspective."

Demcizumab was generally well tolerated in combination with both gemcitabine and Abraxane with fatigue, hypertension, nausea and vomiting being the most common drug-related toxicities. No demcizumab-related reversible cardiotoxicity events have occurred with the implementation of regular monitoring, a truncated treatment approach and cardioprotective medication, if indicated. The combination of gemcitabine with or without Abraxane did not appear to influence the pharmacokinetics of demcizumab.  

Three of the six (50%) evaluable patients who received the demcizumab/gemcitabine/Abraxane combination had partial responses as measured by RECIST and two patients had stable disease resulting in a clinical benefit rate of 83%. A randomized Phase 2 clinical trial in patients with first-line pancreatic cancer is planned for the second half of 2014. "These are the first results from this ongoing study to include the addition of Abraxane to the demcizumab plus gemcitabine combination, building off the positive interim data presented at the October 2013 AACR-NCI-EORTC meeting in Boston," said Jakob Dupont, M.D., OncoMed's Chief Medical Officer. "To date, demcizumab has been well tolerated as part of combination therapy, and we are seeing early indications of notable anti-cancer activity with the triple-drug combination."

1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG

Markets

DOW 18,120.18 -42.81 -0.24%
S&P 500 2,120.66 -2.82 -0.13%
NASDAQ 5,095.9760 -10.6170 -0.21%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs